NO325178B1 - Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. - Google Patents
Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. Download PDFInfo
- Publication number
- NO325178B1 NO325178B1 NO19991591A NO991591A NO325178B1 NO 325178 B1 NO325178 B1 NO 325178B1 NO 19991591 A NO19991591 A NO 19991591A NO 991591 A NO991591 A NO 991591A NO 325178 B1 NO325178 B1 NO 325178B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- chain
- human
- region
- dna
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims description 24
- 239000003814 drug Substances 0.000 title claims description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 229940124597 therapeutic agent Drugs 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 150
- 238000000034 method Methods 0.000 claims description 110
- 239000013604 expression vector Substances 0.000 claims description 82
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 65
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 61
- 235000001014 amino acid Nutrition 0.000 claims description 43
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 22
- 235000004279 alanine Nutrition 0.000 claims description 22
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 18
- 239000004473 Threonine Substances 0.000 claims description 18
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 201
- 241000699666 Mus <mouse, genus> Species 0.000 description 183
- 239000013612 plasmid Substances 0.000 description 175
- 108020004414 DNA Proteins 0.000 description 148
- 238000003752 polymerase chain reaction Methods 0.000 description 115
- 230000027455 binding Effects 0.000 description 88
- 230000000694 effects Effects 0.000 description 82
- 239000002585 base Substances 0.000 description 68
- 239000002299 complementary DNA Substances 0.000 description 53
- 239000000427 antigen Substances 0.000 description 52
- 108091007433 antigens Proteins 0.000 description 52
- 102000036639 antigens Human genes 0.000 description 52
- 238000010276 construction Methods 0.000 description 45
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 42
- 230000003505 mutagenic effect Effects 0.000 description 38
- 231100000219 mutagenic Toxicity 0.000 description 37
- 239000012634 fragment Substances 0.000 description 35
- 230000005764 inhibitory process Effects 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 33
- 238000002965 ELISA Methods 0.000 description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 241000588724 Escherichia coli Species 0.000 description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 108091008146 restriction endonucleases Proteins 0.000 description 23
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 22
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 22
- 230000000259 anti-tumor effect Effects 0.000 description 21
- 238000005259 measurement Methods 0.000 description 21
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 20
- 239000012636 effector Substances 0.000 description 19
- 210000004408 hybridoma Anatomy 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 230000003013 cytotoxicity Effects 0.000 description 18
- 231100000135 cytotoxicity Toxicity 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 239000012228 culture supernatant Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 13
- 229960001924 melphalan Drugs 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000002054 transplantation Methods 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 12
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 108091035707 Consensus sequence Proteins 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 239000011543 agarose gel Substances 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
- 238000011579 SCID mouse model Methods 0.000 description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229960000310 isoleucine Drugs 0.000 description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 8
- 210000004180 plasmocyte Anatomy 0.000 description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 238000013207 serial dilution Methods 0.000 description 7
- 108020004491 Antisense DNA Proteins 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 239000003816 antisense DNA Substances 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000012531 culture fluid Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000609499 Palicourea Species 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 231100001083 no cytotoxicity Toxicity 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229930182817 methionine Chemical group 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 229940124295 CD38 monoclonal antibody Drugs 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108091060210 Heavy strand Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000021161 Plasma cell disease Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 102000047829 human BST2 Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26475696 | 1996-10-04 | ||
| PCT/JP1997/003553 WO1998014580A1 (en) | 1996-10-04 | 1997-10-03 | Reconstituted human anti-hm1.24 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO991591D0 NO991591D0 (no) | 1999-03-31 |
| NO991591L NO991591L (no) | 1999-06-01 |
| NO325178B1 true NO325178B1 (no) | 2008-02-11 |
Family
ID=17407753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19991591A NO325178B1 (no) | 1996-10-04 | 1999-03-31 | Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6699974B2 (cs) |
| EP (1) | EP0960936B1 (cs) |
| KR (1) | KR100388256B1 (cs) |
| CN (2) | CN1271205C (cs) |
| AT (1) | ATE512224T1 (cs) |
| AU (1) | AU715156B2 (cs) |
| BR (1) | BR9712488A (cs) |
| CA (1) | CA2267072C (cs) |
| CZ (1) | CZ296790B6 (cs) |
| IL (1) | IL129286A0 (cs) |
| NO (1) | NO325178B1 (cs) |
| PL (1) | PL187642B1 (cs) |
| RU (1) | RU2184147C2 (cs) |
| SK (1) | SK44399A3 (cs) |
| TR (1) | TR199900722T2 (cs) |
| TW (1) | TW530064B (cs) |
| UA (1) | UA76934C2 (cs) |
| WO (1) | WO1998014580A1 (cs) |
| ZA (1) | ZA978865B (cs) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2177805C2 (ru) * | 1997-02-12 | 2002-01-10 | Чугаи Сейяку Кабусики Кайся | Средство, применяемое при лечении опухолей лимфатической ткани |
| EP0972524A4 (en) * | 1997-02-28 | 2001-03-28 | Chugai Pharmaceutical Co Ltd | LYMPHOCYTE ACTIVATION INHIBITORS |
| CN1326565C (zh) * | 1997-10-14 | 2007-07-18 | 中外制药株式会社 | 淋巴细胞肿瘤抗体的增强剂 |
| JP3609026B2 (ja) * | 1998-02-25 | 2005-01-12 | 中外製薬株式会社 | 抗ｈｍ１．２４抗体の免疫化学的測定方法 |
| US6602663B1 (en) | 1998-09-18 | 2003-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method for detection or measuring plasmocytoma cells |
| DE60021373T2 (de) | 1999-05-10 | 2006-04-27 | Chugai Seiyaku K.K. | Verfahren der zellkultivierung |
| TWI290832B (en) | 1999-08-23 | 2007-12-11 | Chugai Pharmaceutical Co Ltd | Expression enhancer for HM1.24 antigen |
| WO2001077362A1 (fr) * | 2000-04-06 | 2001-10-18 | Chugai Seiyaku Kabushiki Kaisha | Dosage immunologique d'anticorps anti hm1 . 24 |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| JP4450555B2 (ja) * | 2000-12-28 | 2010-04-14 | 協和発酵キリン株式会社 | 新規モノクローナル抗体 |
| WO2002064159A1 (fr) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs affectant les organes hematopoietiques |
| ES2869895T3 (es) | 2001-03-09 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Método de purificación de proteínas |
| WO2002076499A2 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| JP4297689B2 (ja) * | 2001-04-13 | 2009-07-15 | 中外製薬株式会社 | 抗原の発現量を定量する方法 |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| PT1411118E (pt) * | 2001-06-22 | 2008-12-09 | Chugai Pharmaceutical Co Ltd | Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 |
| JP2004536835A (ja) * | 2001-07-09 | 2004-12-09 | アフトン コーポレーション | 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止 |
| JP3792698B2 (ja) | 2002-02-14 | 2006-07-05 | 中外製薬株式会社 | 抗体含有溶液製剤 |
| US20080219974A1 (en) * | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
| JP4753578B2 (ja) * | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| WO2004019966A1 (ja) | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
| WO2004024752A1 (ja) * | 2002-09-11 | 2004-03-25 | Chugai Seiyaku Kabushiki Kaisha | タンパク質精製方法 |
| US20060020119A1 (en) * | 2004-03-29 | 2006-01-26 | Stephen Grimes | Monoclonal antibodies to gastrin hormone |
| JP4689597B2 (ja) * | 2003-03-28 | 2011-05-25 | レセプター バイオロジックス インク． | ガストリンホルモン免疫アッセイ |
| WO2005012531A2 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
| JPWO2005014651A1 (ja) * | 2003-08-11 | 2006-11-24 | 中外製薬株式会社 | 糖鎖改変抗ｈｍ１．２４抗体 |
| WO2005034994A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 固形腫瘍治療剤 |
| EP2077282B1 (en) | 2003-11-05 | 2016-12-28 | Roche Glycart AG | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| US20060122377A1 (en) * | 2004-02-19 | 2006-06-08 | Genentech, Inc. | CDR-repaired antibodies |
| AU2005286164B2 (en) | 2004-09-22 | 2012-05-24 | Cancer Advances Inc. | Monoclonal antibodies to progastrin |
| AU2012216702B2 (en) * | 2005-08-26 | 2014-12-04 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
| AR055137A1 (es) * | 2005-08-26 | 2007-08-08 | Glycart Biotechnology Ag | Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| CA2660795C (en) * | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JP6294585B2 (ja) | 2009-09-03 | 2018-03-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｇｉｔｒ抗体 |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| JP6176849B2 (ja) | 2011-07-19 | 2017-08-09 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| CA2847302C (en) | 2011-09-01 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
| BR112016014824A2 (pt) | 2013-12-27 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para purificar anticorpo que tem ponto isoelétrico baixo |
| EP3185004A4 (en) | 2014-08-20 | 2018-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| AU2018283284B2 (en) | 2017-06-15 | 2024-05-16 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| CN109748964B (zh) * | 2017-11-01 | 2020-11-17 | 深圳宾德生物技术有限公司 | CD317单链抗体317scFv、其编码序列及制备方法和应用 |
| CN113226367B (zh) | 2018-04-06 | 2025-05-06 | Atyr医药公司 | 包括抗nrp2抗体的组合物和方法 |
| WO2019225568A1 (ja) | 2018-05-21 | 2019-11-28 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
| CN112243423B (zh) | 2018-05-28 | 2022-11-04 | 中外制药株式会社 | 填充喷嘴 |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| WO2023058723A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | プレフィルドシリンジ製剤の調製方法 |
| JP7544986B2 (ja) | 2022-04-26 | 2024-09-03 | 中外製薬株式会社 | 医薬製剤含有フィルター内蔵シリンジ |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO873164L (no) * | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| EP0771208B1 (en) * | 1994-08-12 | 2005-10-19 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| RU2177805C2 (ru) * | 1997-02-12 | 2002-01-10 | Чугаи Сейяку Кабусики Кайся | Средство, применяемое при лечении опухолей лимфатической ткани |
| US20020034507A1 (en) * | 1997-02-28 | 2002-03-21 | Yasuo Koishihara | Inhibitor of lymphocyte activation |
| IL135221A0 (en) * | 1997-10-03 | 2001-05-20 | Chugai Pharmaceutical Co Ltd | Natural humanized antibody and methods for the preparation thereof |
| CN1326565C (zh) * | 1997-10-14 | 2007-07-18 | 中外制药株式会社 | 淋巴细胞肿瘤抗体的增强剂 |
| CA2492092A1 (en) * | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
-
1997
- 1997-03-10 UA UA99042469A patent/UA76934C2/uk unknown
- 1997-10-03 TW TW086114474A patent/TW530064B/zh not_active IP Right Cessation
- 1997-10-03 EP EP97942246A patent/EP0960936B1/en not_active Expired - Lifetime
- 1997-10-03 AT AT97942246T patent/ATE512224T1/de not_active IP Right Cessation
- 1997-10-03 CA CA002267072A patent/CA2267072C/en not_active Expired - Fee Related
- 1997-10-03 RU RU99109034/13A patent/RU2184147C2/ru not_active IP Right Cessation
- 1997-10-03 CN CNB971992150A patent/CN1271205C/zh not_active Expired - Fee Related
- 1997-10-03 CN CNA2005100687876A patent/CN1765928A/zh active Pending
- 1997-10-03 PL PL97332742A patent/PL187642B1/pl not_active IP Right Cessation
- 1997-10-03 US US09/269,921 patent/US6699974B2/en not_active Expired - Lifetime
- 1997-10-03 ZA ZA9708865A patent/ZA978865B/xx unknown
- 1997-10-03 TR TR1999/00722T patent/TR199900722T2/xx unknown
- 1997-10-03 AU AU43992/97A patent/AU715156B2/en not_active Ceased
- 1997-10-03 IL IL12928697A patent/IL129286A0/xx not_active IP Right Cessation
- 1997-10-03 SK SK443-99A patent/SK44399A3/sk unknown
- 1997-10-03 BR BR9712488-5A patent/BR9712488A/pt not_active Application Discontinuation
- 1997-10-03 WO PCT/JP1997/003553 patent/WO1998014580A1/ja not_active Ceased
- 1997-10-03 CZ CZ0117399A patent/CZ296790B6/cs not_active IP Right Cessation
- 1997-10-03 KR KR10-1999-7002902A patent/KR100388256B1/ko not_active Expired - Fee Related
-
1999
- 1999-03-31 NO NO19991591A patent/NO325178B1/no unknown
-
2002
- 2002-08-13 US US10/218,253 patent/US7892543B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU715156B2 (en) | 2000-01-20 |
| SK44399A3 (en) | 2000-05-16 |
| TR199900722T2 (xx) | 1999-12-21 |
| KR20000048884A (ko) | 2000-07-25 |
| US20030129185A1 (en) | 2003-07-10 |
| NO991591D0 (no) | 1999-03-31 |
| CN1765928A (zh) | 2006-05-03 |
| HK1024261A1 (en) | 2000-10-05 |
| EP0960936A4 (en) | 2005-01-19 |
| CZ296790B6 (cs) | 2006-06-14 |
| PL187642B1 (pl) | 2004-08-31 |
| CN1235639A (zh) | 1999-11-17 |
| EP0960936A1 (en) | 1999-12-01 |
| BR9712488A (pt) | 1999-10-19 |
| CA2267072C (en) | 2004-11-30 |
| PL332742A1 (en) | 1999-10-11 |
| IL129286A0 (en) | 2000-02-17 |
| ATE512224T1 (de) | 2011-06-15 |
| EP0960936B1 (en) | 2011-06-08 |
| AU4399297A (en) | 1998-04-24 |
| CN1271205C (zh) | 2006-08-23 |
| WO1998014580A1 (en) | 1998-04-09 |
| ZA978865B (en) | 1998-04-20 |
| NO991591L (no) | 1999-06-01 |
| UA76934C2 (en) | 2006-10-16 |
| CA2267072A1 (en) | 1998-04-09 |
| US20030045691A1 (en) | 2003-03-06 |
| RU2184147C2 (ru) | 2002-06-27 |
| US7892543B2 (en) | 2011-02-22 |
| KR100388256B1 (ko) | 2003-06-19 |
| TW530064B (en) | 2003-05-01 |
| CZ117399A3 (cs) | 1999-09-15 |
| US6699974B2 (en) | 2004-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325178B1 (no) | Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. | |
| US7052873B2 (en) | Natural human antibody | |
| FI108917B (fi) | Menetelmä terapeuttisesti käyttökelpoisten CD4-spesifisen yhdistelmävasta-aineen valmistamiseksi | |
| US7332582B2 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
| US20130071385A1 (en) | Monoclonal antibodies | |
| JP2005509414A (ja) | 腫瘍壊死因子関連アポトーシス誘導リガンドレセプターに対して選択的な抗体およびその使用 | |
| JP3587664B2 (ja) | 再構成ヒト抗ｈｍ１．２４抗体 | |
| JP3587843B2 (ja) | 再構成ヒト抗ｈｍ１．２４抗体 | |
| AU725867B2 (en) | Reconstituted human anti-HM1.24 antibody | |
| JP4115425B2 (ja) | 再構成ヒト抗ｈｍ１．２４抗体 | |
| HK1023366A (en) | Reconstituted human anti-hm1.24 antibody | |
| AU2009288700B2 (en) | Monoclonal antibodies | |
| HK1029372A (en) | Natural human antibody |